| Not Yet Recruiting | Adhesion and Safety of Rotigexole Compared to Neupro® NCT07015346 | Eva Pharma | N/A |
| Enrolling By Invitation | Prolactin, Inflammation, and Parkinson's Severity NCT07163156 | Çanakkale Onsekiz Mart University | — |
| Recruiting | A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early P NCT06680830 | Neuron23 Inc. | Phase 2 |
| Recruiting | Reliability and Validity Study of the Turkish Version of the Parkinson's Disease Dyskinesia Scale (PDYS-26) NCT07023224 | Izmir Bakircay University | — |
| Completed | Phase 2a Study of VTX3232 in Parkinson's Disease NCT06556173 | Zomagen Biosciences Ltd. | Phase 2 |
| Completed | Effects of Sensory-Motor Integration Training in Patients with Idiopathic Parkinson's Disease NCT06390163 | Hacettepe University | N/A |
| Completed | A Prospective Study to Evaluate the Correlation Between Oculometric Measurements and Clinical Endpoints in PD NCT05437003 | NeuraLight | N/A |
| Withdrawn | Study to Assess the Safety of MRx0029 or MRx0005 Compared to Placebo, in People With Parkinson's NCT05832775 | 4D pharma plc | Phase 1 |
| Completed | Adipose-derived Stromal Vascular Fraction Cells to Treat Parkinson NCT05699161 | Samuel Vilchez, PhD | Phase 1 / Phase 2 |
| Completed | Feasibility of Motor-cognitive Home Training for Parkinson's Disease Using eHealth Technology NCT05027620 | Stiftelsen Stockholms Sjukhem | N/A |
| Withdrawn | Effect of Meditation and Controls and Subjects With Parkinson's Disease on Brain Activity Measured by fMRI Wit NCT05103618 | Andrew Newberg | Phase 2 |
| Unknown | Multicenter Study of Blood Biomarkers of Mitochondrial and Peroxisomal Metabolism to Differentiate Idiopathic NCT05110547 | Centre Hospitalier Universitaire Dijon | — |
| Active Not Recruiting | FDOPA PET and Nutritional Support in Parkinson's Disease NCT04459052 | Thomas Jefferson University | Phase 2 |
| Completed | Effect of Safinamide on Parkinson's Disease Related Chronic Pain NCT03841604 | Zambon SpA | Phase 4 |
| Active Not Recruiting | A Study to Evaluate in Patients With Parkinsonian Type Disorders NCT03683225 | Chase Therapeutics Corporation | Phase 2 |
| Completed | Molecular Pathology and Neuronal Networks in LRRK2 Parkinson's Disease NCT03782753 | King's College London | — |
| Withdrawn | The Natural History of Parkinson's Disease-associated Spinal Disorders NCT04101513 | Ohio State University | — |
| Completed | Lundbeck TOMs Orthostatic Hypotension NCT04510922 | Alberto Espay, MD, MSc | Phase 4 |
| Completed | Intravenous Plasma Treatment for Parkinson's Disease NCT04202757 | The Neurology Center | EARLY_Phase 1 |
| Completed | Voice Treatment for Parkinson's Disease NCT03700684 | University of Massachusetts, Amherst | N/A |
| Completed | Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide) NCT03944785 | Supernus Pharmaceuticals, Inc. | — |
| Terminated | Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Dise NCT03051607 | Biotie Therapies Inc. | Phase 3 |
| Completed | Measuring Parkinson's Disease With Tear Fluid NCT03037463 | University of Southern California | — |
| Unknown | tDCS for Treatment of Depression in Parkinson's Disease NCT02960464 | Hospital Santa Marcelina | N/A |
| Completed | Sleep, Awake & Move - Part I NCT02723396 | Neurocenter of Southern Switzerland | — |
| Completed | Efficacy Phase IIa Study of CVXL-0107 in Advanced Parkinson's Disease NCT02641054 | CleveXel Pharma | Phase 2 |
| Completed | PA Behavior and HRQoL in Parkinson's Disease Patients Patients: Role of Social Cognitive Variables NCT05575479 | Ohio State University | — |
| Terminated | Quantification of Dopamine Active Transporter (DAT) in Humans: Validation of a New Radiophamaceutical, the [18 NCT02393027 | University Hospital, Tours | EARLY_Phase 1 |
| Completed | A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopath NCT02373072 | Pfizer | Phase 1 |
| Unknown | Parkinsonian Brain Repair Using Human Stem Cells NCT02780895 | Celavie Bioscences, LLC | Phase 1 |
| Completed | Physiological Effects of Nutritional Support in Patients With Parkinson's Disease NCT02445651 | Thomas Jefferson University | N/A |
| Unknown | Evaluation of Safety and Tolerability of Fetal Mesencephalic Dopamine Neuronal Precursor Cells for Parkinson's NCT01860794 | Bundang CHA Hospital | Phase 1 / Phase 2 |
| Completed | GDNF in ideopathicParkinsons Disease NCT03652363 | North Bristol NHS Trust | Phase 2 |
| Completed | Study to Determine Mutations in the Gaucher Gene in Patients With Idiopathic Parkinson's Disease for Phenotype NCT01272687 | CENTOGENE GmbH Rostock | — |
| Completed | Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037) NCT01227265 | Merck Sharp & Dohme LLC | Phase 3 |
| Terminated | An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153) NCT01215227 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Study on the Tolerability of Duloxetine in Depressed Patients With Parkinson's Disease NCT00437125 | Eli Lilly and Company | Phase 4 |
| Completed | Transdermal Rotigotine User Surveillance Study NCT00599339 | UCB Pharma | — |
| Completed | Levetiracetam Treatment in Adult Subjects With Parkinson's Disease Experiencing Troublesome Dyskinesias NCT00160576 | UCB Pharma | Phase 2 |